-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

Benzinga·08/07/2026 13:58:25
Listen to the news
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.